Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

NCT00585377 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: Bevacizumab and Erlotinib

Sponsor

University of Utah

Collaborators

[object Object]